Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-14 · accession 0000875320-25-000079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-19 | 2025-02-14 | VRTX | Ambrose Kristen | SVP, CAO | F - Tax | $463.46 | -564 | 11.5K | -5% | -$261.4K | |
| 2025-02-19 | 2025-02-18 | VRTX | Ambrose Kristen | SVP, CAO | S - Sale | $455.06 | -671 | 10.8K | -6% | -$305.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-14 | F | D | 564 | $463.46 | 11,469 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-18 | S | D | 671 | $455.06 | 10,798 | D | — | — |